Phathom Pharmaceuticals Inc (PHAT)
18.98
+0.70
(+3.86%)
USD |
NASDAQ |
Nov 04, 16:00
18.94
-0.04
(-0.18%)
After-Hours: 20:00
Phathom Pharmaceuticals Research and Development Expense (TTM): 42.46M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 42.46M |
| March 31, 2024 | 47.85M |
| December 31, 2023 | 49.90M |
| September 30, 2023 | 52.45M |
| June 30, 2023 | 59.21M |
| March 31, 2023 | 65.26M |
| December 31, 2022 | 71.44M |
| September 30, 2022 | 69.05M |
| June 30, 2022 | 66.64M |
| March 31, 2022 | 69.42M |
| December 31, 2021 | 72.34M |
| Date | Value |
|---|---|
| September 30, 2021 | 100.44M |
| June 30, 2021 | 109.60M |
| March 31, 2021 | 102.86M |
| December 31, 2020 | 98.15M |
| September 30, 2020 | 69.20M |
| June 30, 2020 | 47.90M |
| March 31, 2020 | 114.71M |
| December 31, 2019 | 99.27M |
| September 30, 2019 | 86.58M |
| June 30, 2019 | 82.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
42.46M
Minimum
Jun 2024
114.71M
Maximum
Mar 2020
74.11M
Average
69.20M
Median
Sep 2020
Research and Development Expense (TTM) Benchmarks
| Fortress Biotech Inc | 71.93M |
| NovaBay Pharmaceuticals Inc | 0.043M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |